Real-World Survival Benefit With CDK4/6 Inhibitors in MBC Real-World Survival Benefit With CDK4/6 Inhibitors in MBC

Registry data confirm an overall survival benefit when a CDK4/6 inhibitor is added to endocrine therapy in HR-positive metastatic breast cancer.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news